Dive into the latest breakthroughs and transformative trends at the intersection of psychedelics, cannabis, and AI-driven research. Embrace the cutting-edge developments reshaping our understanding and approach to mental and spiritual health.

Welcome to the special leap year edition of the SykoActive Studios Daily Digest, your premier source for the latest and most impactful developments from around the globe. Today, we're exploring groundbreaking advancements and transformative insights that are reshaping our world.

In a landmark step for addiction treatment, Awakn Life Sciences Corp. has received the green light to commence Phase III clinical trials for its pioneering treatment, AWKN-P001, targeting Severe Alcohol Use Disorder (SAUD).

A recent study involving Special Ops veterans has highlighted the potential benefits of Ibogaine and 5-MeO-DMT treatments in addressing PTSD and enhancing cognitive abilities.

Psychonauts waited for over an hour outside a Portland Mushroom Supplement Store, with lines wrapping around the building, to get their hands on some psychedelic mushrooms before they sold out.